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MansouraAbstract Introduction: Seronegative spondyloarthritis (SpA) is a group of chronic potentially dis-
abling diseases that affect mainly axial joints in addition to extra-articular manifestations such as
enthesitis, dactylitis and uveitis.
Aim of the work: To assess the demographic features, clinical manifestations and radiological
ﬁndings of SpA in Egyptian patients.
Patients and methods: Fifty-three SpA patients were recruited from the Rheumatology and
Immunology Unit of Mansoura University Hospital. Demographic, clinical and therapeutic data
were collected. Skin was carefully assessed for psoriasis. Erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP) were measured. All patients were evaluated by conventional radio-
graphs of hands, knees, ankles, sacroiliac joints (SIJ) and lumbosacral spines in addition to mag-
netic resonance imaging (MRI) of the SIJs.
Results: Ankylosing spondylitis (AS) was the most prevalent (55%) followed by psoriatic arthri-
tis (PsA) (38%) and 2 patients had enteropathic arthritis, one had reactive arthritis and another had
undifferentiated SpA. The mean age of the patients was 39 ± 10.8 years; disease duration was 10
± 3.5 years with a male predominance (58%). Inﬂammatory low back pain was present in all the
patients and 77.4% had both axial and peripheral arthritis. Extra-articular manifestations as enthe-
sitis, bursitis and dactylitis were detected in only 9.4% of patients. Sacroiliitis was detected in 81.1%
of patients using conventional radiographs. MRI detected bone marrow edema in 9.4%, narrowing
in 11.3%, sclerosis in 17% and ankylosis in 52.8%., Egypt.
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are comparable to those from other countries except for the lower prevalence of extra-articular
manifestations.
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Seronegative spondyloarthritis (SpA) is a group of chronic
inﬂammatory rheumatic diseases that affect the axial and/or
peripheral joints [1]. The disease is usually seen between second
and fourth decades of life [2]. The incidence of SpA varies,
depending on the examined populations, from 0.2% to 1.9%
[3]. Males are more affected than females. Apart from genetic
factors, environmental factors also seem to play a role in the
multifactorial causes of SpA. These diseases all share a com-
mon clinical pattern and pathophysiological mechanisms [4].
Sacroiliitis is the hallmark of the disease [5], however, enthesi-
tis, dactylitis and uveitis are also common features of SpA [6].
Seronegative SpA diseases include ankylosing spondylitis
(AS), psoriatic arthritis (PsA), reactive arthritis (ReA), and
enteropathic arthritis (EntA) for those associated with inﬂam-
matory bowel disease (IBD) and undifferentiated spondy-
loarthritis (uSpA) [7]. Generally there is good symptomatic
response to anti-inﬂammatory doses of nonsteroidal antiin-
ﬂammatory drugs (NSAIDs) [8].
There is a growing interest in early diagnosis for patients
with SpA which is a disease condition deﬁned by a combina-
tion of symptoms and signs. Multiple imaging modalities
including conventional radiography, magnetic resonance
imaging (MRI) and ultrasonography (US) are available for
evaluation of SpA [9]. The spectrum of joint involvement
should not be limited to sacroiliitis and subclinical peripheral
arthritis has also been reported in Egyptian SpA patients
[10]. Subclinical arthritis was frequently found in patients with
psoriasis by MRI [11].
Quite recently, considerable attention has been paid to eval-
uate the epidemiological distribution and clinical features of
seronegative SpA. However, this issue has not been sufﬁciently
studied in Egypt. In this article we present the demographic,
clinical and radiological characteristics as well as the therapeu-
tic proﬁle of seronegative SpA patients attending the Rheuma-
tology clinic and unit of the Mansoura University Hospital in
Egypt.
2. Patients and methods
In this cross-sectional observational study, 53 consecutive
patients with SpA were recruited from the Rheumatology
and Immunology Unit of Mansoura University Hospital.
Written informed consent was obtained from all patients after
informing them about the study purposes. The study was
approved by the ethics committee of the Mansoura University.
The diagnosis of seronegative SpA was conﬁrmed accord-
ing to Assessment of SpondyloArthritis international Society
(ASAS) endorsed criteria for classifying patients with axial
[12] and peripheral SpA [13] as well as CASPAR criteria for
PsA [14]. Any patient with overlap with other rheumatic dis-
eases was excluded. Demographic data were collected includ-A et al. Demographic, clinical and ra
, The Egyptian Rheumatologist (2016),ing age, sex and socioeconomic status. Disease duration was
recorded and clinical data were evaluated including the pres-
ence of inﬂammatory low back pain (ILBP) at the onset of
the disease. Axial or peripheral joints involvement was deter-
mined and any associated periarticular manifestations like
enthesitis and bursitis were also evaluated. Toes and ﬁngers
were carefully examined searching for any signs of acute or
chronic dactylitis. Skin was carefully assessed searching for
any psoriatic skin lesions. Additionally, detailed information
was obtained regarding history of diabetes mellitus, hyperten-
sion, past history of uveitis and family history of seronegative
SpA.
The erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) were recorded. Descriptive therapeutic history
including NSAIDs, local and systemic steroids, conventional
and biological disease modifying antirheumatic drugs
(DMARDs) was obtained. All patients were evaluated by con-
ventional radiographs of hands, knees, ankles, sacroiliac joints
(SIJ) and lumbosacral spines in addition to MRI of the SIJs. In
AS patients, disease activity was assessed using the Bath anky-
losing spondylitis disease activity index (BASDAI) [15].
Statistical analysis: Statistical Package for Social Science
(SPSS) program version 15 was used for an analysis of data.
Data were summarized using mean and standard deviation
(mean ± SD) for quantitative and numbers and percentages
for categorical variables. p-Value < 0.05 was considered
signiﬁcant.
3. Results
A total of 53 SpA patients were included, which accounted for
0.8% of patients attending the Rheumatology clinic and unit.
Of them, 29 (55%) were AS, 20 (38%) were PsA, 2 (3.8%) had
enteropathic arthritis, 1 (1.9%) with ReA another (1.9%) with
uSpA (Fig. 1). The demographic features, clinical manifesta-
tions, ESR, CRP and therapeutic proﬁle of the studied SpA
patients are presented in Table 1. The mean age of the patients
was 39 ± 10.8 years, with 31 (58%) males and 22 (42%)
females (M:F 1.4:1). The mean disease duration was 10
± 3.5 years. ILBP was present in all patients at the onset of
the disease. Only one patient had monoarthritis, 30 (56.6%)
had oligoarthritis while, 22 (41.5%) patients had polyarthritis.
About one third of the patients had psoriasis. Uveitis was
reported in 6 patients and family history of SpA was evident
in 11 (6 had AS and 5 had PsA).
When evaluating the disease activity in AS patients using
the BASDAI score, none of the patients was inactive. How-
ever, 16 (55.2%) had very high disease activity, 11 (37.9%)
had high and 2 (6.9%) moderate disease activity.
Radiographic ﬁndings of the peripheral joints are shown in
Table 2. Acro-osteolysis was detected in one PsA patient and
arthritis mutilans in another. Radiographic features of the
SIJ are presented in Table 3. By conventional radiographs,diological characteristics of seronegative spondyloarthritis Egyptian patients: A
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Figure 1 Frequency of the distribution of the spondyloarthritis
patients subtypes. AS: ankylosing spondylitis, PsA: psoriatic
arthritis, ReA: reactive arthritis, EntA: enteropathic arthritis,
uSpA: undifferentiated spondyloarthritis.
Table 1 Demographic features, clinical characteristics, ESR,
CRP and therapeutic proﬁle of the spondyloarthritis patients.
Characteristics mean ± SD or n (%) SpA patients (n= 53)
Age (years) 39 ± 10.8
Sex (M:F) 31:22
Low socio-economic status 44 (83)
Disease duration
<1 year 3 (5.7)
3–5 years 18 (34)
5–10 years 9 (17)
>10 years 23 (43.4)
ILBP at disease onset 53 (100)
Peripheral joints aﬀected
<2 joints 1 (1.9)
2–4 joints 30 (56.6)
5–10 joints 22 (41.5)
Arthritis
Axial 9 (17)
Peripheral 3 (5.7)
Both 41 (77.4)
Peripheral arthritis
Upper limb joints 4 (7.5)
Lower limb joints 15 (28.3)
Both 25 (47.2)
Enthesitis 5 (9.4)
Dactylitis 5 (9.4)
Bursitis 5 (9.4)
Psoriasis 20 (37.7)
Uveitis 6 (11.3)
Family history of SpA 11 (20.8)
Hypertension 3 (5.7)
Diabetes mellitus 7 (13.2)
ESR 44.7 ± 24.3
CRP 15.5 ± 12.2
Medications NSAIDs 53 (100)
Conventional DMARDs 30 (56.6)
Systemic steroids 30 (56.6)
Local steroid injection 8 (15)
Inﬂiximab 30 (56.6)
Etanercept 2 (5.8)
SpA: spondyloarthritis, ILBP: inﬂammatory low back pain, ESR:
erythrocyte sedimentation rate, CRP: C-reactive protein, NSAIDs:
non-steroidal anti-inﬂammatory drugs, DMARDs: disease modi-
fying antirheumatic drugs.
Characteristics of seronegative spondyloarthritis Egyptian patients 343 (81.1%) showed evidence of sacroiliitis. MRI of the SIJs
was normal in 9.4% of patients while ankylosis was detected
in 52.8%. X-ray hand in a PsA patient showing multiple joints
deformities is presented in Fig. 2 and of the SIJ in an AS
patient in Fig. 3.
4. Discussion
Seronegative SpA denotes a family of inﬂammatory arthritides
that include AS, PsA, ReA and enteropathic arthritis associ-
ated with IBD [16]. It is well known that the prevalence of
seronegative SpA shows considerable differences among ethnic
groups and populations [17] and globally reported to be 1%
[18]. The prevalence of SpA was calculated as 0.32–1.73% in
Europe [19], 0.45% in southern Sweden [20], 0.01% in Japan
[21] and 2.5% in Northern Arctic natives. The exact prevalence
of SpA in the United States is not clear. This variation in
prevalence of SpA as a disease may be attributed to geographic
variation in the prevalence of HLA-B27. Also, it may be
explained by variation in quality and bias of the methodologic
approaches.
The frequency of males with SpA was slightly increased
than that of females. In agreement a sex ratio of SpA in favor
of males has been reported [21,22]. It is not surprisingly that all
studied patients had ILBP at disease onset as the SpA diseases
affect mainly axial joints. Similarly, ILBP was present in all
Tunisian AS patients [23]. Enthesitis, which is a characteristic
feature of SpA diseases, were only found in 9.4% of cases. On
the contrary, 64.4% of the entheseal sites in Egyptian patients
with early SpA were abnormal by ultrasonography [9].
The NSAIDs were considered the drug of choice by the
SpA patients for pain and stiffness. Interest in NSAIDs as
disease-modifying agents has been rekindled by data indicating
reduced progression in patients on continuous, as opposed to
on-demand, treatment [24]. Besides the dramatic, well demon-
strated symptomatic effect, NSAIDs might be able to reduce
the level of acute phase reactants [25] and was reported to
retard radiological progression of the spine when given daily
at a high dose [26]. Systemic steroids were used by about halfPlease cite this article in press as: Abdelsalam A et al. Demographic, clinical and ra
rheumatology clinic experience in Mansoura, The Egyptian Rheumatologist (2016),of the patients. However, this was not associated with speciﬁc
indications like uveitis. It may be due to the limited availability
and high cost of biological therapy in Egypt. However, almost
half of the patients have recently received biological therapy
either inﬂiximab or etanercept.
In the present study, all patients had ILBP and affection of
both axial and peripheral arthritis was the most common pre-
sentation in SpA. This was in agreement with the study con-
ducted by Saad et al. [27]. In a study on Egyptian patients
with early SpA, peripheral arthritis was found in 44.4% and
axial involvement in 42.2% [9]. Oligoarthritis (56.6%) was
more common than polyarthritis (41.5%) and AS represented
the most common disease subtype among SpA patients. AS isdiological characteristics of seronegative spondyloarthritis Egyptian patients: A
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Table 2 Conventional radiological features of the peripheral
joints involved in spondyloarthritis patients.
Peripheral joints X-ray features n (%) SpA patients (n= 53)
Normal 32 (60.4)
Soft tissue swelling 19 (35.8)
Joint space narrowing 20 (37.7)
Periarticular osteoporosis 20 (37.7)
Joint deformities 7 (13.2)
Acro-osteolysis 1 (1.9)
Arthritis mutilans 1 (1.9)
SpA: spondyloarthritis.
Table 3 Radiological features of the sacroiliac joints in
spondyloarthritis patients.
SIJ radiological features n (%) SpA patients (n= 53)
Plain X-ray Grade 0 10 (18.9)
Grade 1 5 (9.4)
Grade 2 6 (11.3)
Grade 3 7 (13.2)
Grade 4 25 (47.2)
MRI Normal 5 (9.4)
BME 5 (9.4)
Narrowing 6 (11.3)
Sclerosis 9 (17)
Ankylosis 28 (52.8)
SpA: spondyloarthritis, SIJ: sacroiliac joint, MRI: magnetic reso-
nance imaging, BME: bone marrow edema.
Figure 2 Posteroanterior radiograph of the hand in a psoriatic
arthritis patient showing multiple joints deformities.
Figure 3 Frontal radiograph of the sacroiliac joints (SIJ) in
ankylosing spondylitis patient showing ankylosed right SIJ with
subchondral bone sclerosis at the left.
4 A. Abdelsalam et al.the most widely recognized representative of SpA diseases [17].
AS was the most prevalent in population-based studies con-
ducted in Greece [22] and in the United States [28] while PsAPlease cite this article in press as: Abdelsalam A et al. Demographic, clinical and ra
rheumatology clinic experience in Mansoura, The Egyptian Rheumatologist (2016),was the commonest in Italy [29] and Finland [30]. However,
some hospital based studies from India have reported uSpA
to be the commonest subset [31,32]. Psoriatic skin lesions were
detected in about one third of the patients, this percentage rep-
resents the patients diagnosed as PsA. Disease distribution dif-
fers according to ethnicity. In the USA, PsA comprised 36.4%
of the SpA population [33] and was 34.8% in Greece [22]. PsA
is highly prevalent in Argentina (60.2%) but is much lower in
Brazil (13.7%) and Guatemala (10%) [27].
In this study, uveitis was present in 6 (11.3%) patients. Sim-
ilarly, uveitis was reported in 18.6% of Chilean SpA patients
[34] and in 20% of Egyptian SpA patients [9]. It was the most
frequent extraarticular feature in SpA [35] that was reported to
develop in 25% of AS patients and up to 10% with early PsA
[36]. The prevalence increases with disease duration and is
higher in HLA-B27- positive [37].
Importantly, family history of SpA, AS followed by PsA,
was positive in 11 (20.8%) of the studied patients. Family his-
tory was well reported in SpA cases, more in AS due to genetic
factor and association of HLA-B27 [38].
By plain X-ray, normal peripheral joints and SIJs were pre-
sent in 60.4% and 18.9% respectively, while the rest of the
patients had sclerosis, narrowing and ankylosis of SIJs. MRI
on the sacroiliac joints showed ankylosis in about half of the
patients. This may contribute to long disease duration, defec-
tive therapy and delayed treatment with biological therapy
[39]. Spondyloarthropathies (SpA) are a group of disorders
that primarily affect the synovial joints of the axial and appen-
dicular skeleton of variable predilections. Plain radiography is
the initial and standard method of investigation in axial SpAs.
However, MRI has been increasingly used in evaluating SpAs
during the early phases of the disease or when radiographic
ﬁndings are equivocal [40]. The role of imaging in the evalua-
tion and management of SpA has experienced a resurgence of
interest with the introduction of MRI [41]. Different types of
SpAs demonstrate different imaging characteristics that are
important to identify to reach the correct diagnosis [40].
The present study is limited by the design of the study
which does not allow follow up of the patients for assessment
of the efﬁcacy of the newly introduced biological therapy. The
number of patients was relatively small and other validated
scores e.g. BASRI were not used.diological characteristics of seronegative spondyloarthritis Egyptian patients: A
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Characteristics of seronegative spondyloarthritis Egyptian patients 5In conclusion, the results of this study show a broad charac-
terization of different aspects of SpA patients in Mansoura
Governorate. These data allow a better understanding of the
disease and therefore may be useful for planning future care
and service demands.
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